China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025)
China Pharma Holdings (CPHI) posted Cash from Investing Activities of -$5767.0 for Q4 2025, up 85.79% on a QoQ basis from -$40598.0 in Q3 2025, and up 97.89% year-over-year from -$2914.3 in Q4 2024.
China Pharma Holdings (CPHI) Cash from Investing Activities (2010 - 2025) Analysis & Trends
China Pharma Holdings' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$5767.0 for Q4 2025.
- Quarterly Cash from Investing Activities rose 97.89% year-over-year to -$5767.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$137251.0 (up 59.1% YoY) and the FY2025 annual result came in at -$137251.0, up 52.95% from the prior year.
- Cash from Investing Activities was -$5767.0 for Q4 2025 at China Pharma Holdings, up from -$40598.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $55964.0 in Q1 2023 and bottomed at -$415977.0 in Q3 2021.
- A 5-year average of -$77337.3 and a median of -$19809.0 in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 4123.29% — and 2024, when it tumbled 5927.21%.
- China Pharma Holdings' Cash from Investing Activities stood at -$7056.0 in 2021, then jumped by 486.45% to $27268.0 in 2022, then plunged by 116.6% to -$4527.0 in 2023, then tumbled by 5927.21% to -$272852.0 in 2024, then surged by 97.89% to -$5767.0 in 2025.
- Business Quant data shows CPHI's Cash from Investing Activities at -$5767.0 in Q4 2025, -$40598.0 in Q3 2025, and -$32562.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 743.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -60.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5,767.00 |
| Dec 31, 2025 | -5,767.00 |
| Sep 30, 2025 | -40,598.00 |
| Sep 30, 2025 | -40,598.00 |
| Jun 30, 2025 | -32,562.00 |
| Jun 30, 2025 | -32,562.00 |
| Mar 31, 2025 | -58,324.00 |
| Mar 31, 2025 | -58,324.00 |
| Dec 31, 2024 | -272,852.00 |
| Dec 31, 2024 | -272,852.00 |
| Sep 30, 2024 | 9,220.00 |
| Sep 30, 2024 | 9,220.00 |
| Dec 31, 2023 | -4,527.00 |
| Dec 31, 2023 | -4,527.00 |
| Sep 30, 2023 | -67,455.00 |
| Sep 30, 2023 | -67,455.00 |
| Jun 30, 2023 | 4,501.00 |
| Jun 30, 2023 | 4,501.00 |
| Mar 31, 2023 | 55,964.00 |
| Mar 31, 2023 | 55,964.00 |